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 Atrial fibrillation (AF) is the most common sustained cardiac rhythm abnormality and 41 
associated with substantial risk of stroke and thromboembolism, leading to low quality of life 42 
and high mortality. Patients with AF are at heightened risk of cognitive decline and dementia, 43 
even in the absence of a medical history of past stroke (1). One factor that potentially 44 
contributes to these complications is an impairment in cerebrovascular reactivity. The 45 
cerebral vasculature is very sensitive to changes in arterial carbon dioxide. Cerebrovascular 46 
CO2 reactivity (CVRCO2) is impaired in several neurodegenerative disorders, and 47 
independently predicts the occurrence of ischemic stroke (2) and cardiovascular mortality. 48 
We aimed to test the hypothesis that CVRCO2 is reduced in AF. 49 
CVRCO2 was determined in patients with AF (n=31, 69 [64, 72] years, median 50 
[interquartile range]), hypertension (n=31, 68 [65, 72] years) and healthy controls (n=30, 69 51 
[66, 73] years), from the slope of the change in middle cerebral artery mean blood flow 52 
velocity (MCAvmean; transcranial Doppler ultrasound) versus end-tidal CO2 partial pressure 53 
(PETCO2) between two 4-min hypercapnic steps of 4% and 7% CO2 (21% Oxygen, Nitrogen 54 
balanced) delivered via the open circuit steady-state method (3). AF patients had a diagnosis 55 
of paroxysmal or persistent AF, whilst hypertensives were also clinically diagnosed (i.e., 56 
consistent non-clinical ambulatory blood pressure of systolic >140 mmHg and/or diastolic 57 
>90 mmHg). Patients with hypertension served as a ‘disease control’ group to account for the 58 
effect of medications and comorbidities. All procedures performed were approved by the 59 
National Research Ethics Service Committee West Midlands (13/WM/0210 and 60 
15/WM/0447) and conformed to the Declaration of Helsinki (2008). 61 
CVRCO2 was 31% lower in patients with AF versus healthy controls and patients 62 
with hypertension (P<0.001) (Figure 1A). Systemic endothelial dysfunction (increased 63 
plasma von Willebrand factor, reduced nitrite/nitrate product and impaired brachial artery 64 
flow-mediated dilatation) has been reported in AF, possibly due to the irregular heart rhythm 65 
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causing alterations in shear stress pattern (5), and may account for the diminished CVRCO2 66 
observed. Cerebral perfusion, (i.e., MCAvmean) was 16% lower in patients with AF (51.0 67 
[12.9] cm·s
-1
, mean [standard deviation]) and 13% lower in patients with hypertension (53.1 68 
[11.1] cm·s
-1
), when compared to healthy controls (60.9 [12.9] cm·s
-1
) (P=0.006). AF patients 69 
that were fibrillating when studied (55% of total) had a lower MCA Vmean (31.1 [8.7] cm·s
-1
) 70 
than those not fibrillating (59.2 [10.5] cm·s
-1
) (P<0.001). Low cerebral perfusion can lead to 71 
vasodilatation of cerebral arterioles, thus reducing vasodilatory reserve and interfering with 72 
cerebral autoregulation. However, CVRCO2 was not different between AF sub-groups 73 
(P=0.303) (Figure 1B) suggesting that baseline cerebral perfusion per se was not a major 74 
determinant of the blunted CVRCO2 response, pointing to another shared factor (e.g., 75 
endothelial dysfunction).  76 
CVRCO2 was not different in hypertensives and normotensives, in agreement with 77 
some, but not all previous studies. These inconsistent findings may be attributable to 78 
differences in patient characteristics (medications, hypertension etiology and severity) and 79 
the methodological approach utilized. A variety of approaches have been developed to 80 
determine CVRCO2 and the relative merits are debated (4). CVRCO2 and MCAvmean showed a 81 
good between-day test-retest reliability (intraclass correlation of 0.938 [95% CI 0.759-0.985] 82 
P<0.001and 0.981 [0.923-0.995] P<0.001; co-efficient of variation for the method error of 83 
6.06% and 2.95%, respectively), and CVRCO2 demonstrated an area under the receiver 84 
operating characteristic curve of 0.78 [0.66, 0.89].  85 
In summary, AF patients had a lower cerebral perfusion and impaired CVRCO2 when 86 
compared to healthy controls. A poor CVRCO2, indicative of a limited cerebral vascular 87 
reserve, may serve as an “early warning” of cerebrovascular dysfunction and worsen stroke 88 
outcome in AF by further compromising the cerebral circulation, increasing infarction size, 89 
and delaying functional recovery after ischemia. AF patients that were fibrillating when 90 
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examined had a worse cerebral perfusion than those who were not. Low cerebral perfusion is 91 
associated with white matter damage and lower cognitive test scores. Collectively, our 92 
observations may have implications for AF-related cognitive decline, cerebrovascular events 93 
and mortality, and require further exploration. 94 
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FIGURE 112 
 113 
Figure 1. Cerebrovascular carbon dioxide reactivity (CVRCO2) in healthy controls (HC), 114 
patients with atrial fibrillation (AF) and hypertension (HT) (left), along with AF-sub- 115 
groups (right). Horizontal bars show mean and standard deviation. *P<0.05 vs. HC and HT.  116 
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